Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2 Inhibitors in the Management of Type 1 Diabetes (T1D): An Update on Current Evidence and Recommendations
Pietro Maffei, Silvia Bettini, Luca Busetto, et al.
Diabetes Metabolic Syndrome and Obesity (2023) Vol. Volume 16, pp. 3579-3598
Open Access | Times Cited: 19

Showing 19 citing articles:

Applications of SGLT2 inhibitors beyond glycaemic control
Daniel V. O’Hara, Carolyn S.P. Lam, John J.V. McMurray, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 8, pp. 513-529
Closed Access | Times Cited: 26
Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets
Allison B. Reiss, Berlin Jacob, Aarij Zubair, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 7, pp. 1881-1881
Open Access | Times Cited: 17
Excessive Initial Renal Function Decline Following Sodium-Glucose Cotransporter-2 Inhibitor Treatment Predicts Major Adverse Cardiorenal Outcomes
Chi‐Yu Chen, Shao‐Sung Huang, Shuo-Ming Ou, et al.
Mayo Clinic Proceedings (2025)
Closed Access | Times Cited: 1
SGLT2 inhibitors in diabetic and non-diabetic kidney transplant recipients: current knowledge and expectations
Erietta Polychronopoulou, Fanny Bourdon, Daniel Teta
Frontiers in Nephrology (2024) Vol. 4
Open Access | Times Cited: 6
Metabolic interventions as adjunctive therapies to insulin in type 1 diabetes: Current clinical landscape and perspectives
Juliana Podobnik, Kacey J. Prentice
Diabetes Obesity and Metabolism (2025)
Open Access
SGLT-2 inhibitors and diabetic ketoacidosis
F. Agozzino, Teresa Falco, Antonio Villa
Internal and Emergency Medicine (2025)
Closed Access
Insulin Resistance in Type 1 Diabetes and Its Treatment Strategies
全昊 孙
Advances in Clinical Medicine (2025) Vol. 15, Iss. 03, pp. 311-317
Closed Access
A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors
Daniel V. O’Hara, Meg Jardine
Diabetes Obesity and Metabolism (2025)
Open Access
Type 1 diabetes presenting in adults: Trends, diagnostic challenges and unique features
Carmella Evans‐Molina, Richard A. Oram
Diabetes Obesity and Metabolism (2025)
Open Access
Update in non-alcoholic fatty liver disease management: role of sodium-glucose cotransporter 2 inhibitors
Oscar René Zambrano-Vásquez, Fernando Cortés-Camacho, Jorge Ismael Castañeda‐Sánchez, et al.
Life Sciences (2025), pp. 123638-123638
Closed Access
Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems—A Literature Review
Viviana Elian, Violeta Popovici, Oana Karampelas, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 1972-1972
Open Access | Times Cited: 3
A Review of Sotagliflozin: The First Dual SGLT-1/2 Inhibitor
Zoya Siddiqui, Niloofar Rasouli, Eliana Felder, et al.
Cardiology in Review (2024)
Closed Access | Times Cited: 3
Metabolic health in people living with type 1 diabetes in Belgium: a repeated cross-sectional study
Astrid Lavens, Christophe De Block, Philippe Oriot, et al.
Diabetologia (2024)
Open Access | Times Cited: 3
Continuous ketone monitoring: Exciting implications for clinical practice
Yee Wen Kong, Dale Morrison, Jean Lu, et al.
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 2
Glucometabolic Efficacy of the Empagliflozin/Metformin Combination in People with Type 1 Diabetes and Increased Cardiovascular Risk: A Sub-Analysis of a Pilot Randomized Controlled Trial
Miodrag Janić, Andrej Janež, Mišo Šabovič, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 22, pp. 6860-6860
Open Access
A Systematic Review and Meta-Analysis of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors and Their Impact on the Management of Heart Failure
Nestor Lemos Ferreira, Abiodun Bamidele Adelowo, Zahid Khan
Cureus (2024)
Open Access
Interventions Targeting Insulin Resistance in Patients with Type 1 Diabetes: A Narrative Review
Andreea Herascu, Vlad Florian Avram, Laura Gaiţă, et al.
Medicina (2024) Vol. 60, Iss. 12, pp. 2067-2067
Open Access
Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications
Basavana Goudra, Geno J. Merli, Michael Green
Pharmaceuticals (2024) Vol. 18, Iss. 1, pp. 4-4
Open Access
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Guardians against Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Heart Diseases
Linh Thi Truc Pham, Supachoke Mangmool, Warisara Parichatikanond
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 11, pp. 3279-3298
Open Access
Page 1

Scroll to top